Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 10
Submit an article Journal homepage
108
Views
20
CrossRef citations to date
0
Altmetric
Research Article

Phase I Study of Gemcitabine (Difluorodeoxycytidine) in Children with Relapsed or Refractory Leukemia (CCG-0955): A Report from the Children's Cancer Group

P.G. Steinherz Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 411, New York, NY 10021-6094, USA
,
N.L. Seibel Children's National Medical Center, Washington, DC, USA
,
M.M. Ames Mayo Clinic, Rochester MN, USA
,
V.I. Avramis Childrens Hospital Los Angeles, Los Angeles, CA, USA
,
M.D. Krailo Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
,
W. Liu-Mares Children's Oncology Group, Arcadia, CA, USA
,
J.M. Reid Mayo Clinic, Rochester MN, USA
,
S.L. Safgren Mayo Clinic, Rochester MN, USA
&
G.H. Reaman Children's National Medical Center, Washington, DC, USA
 show all
Pages 1945-1950 | Published online: 03 Aug 2009

  • [Line 8018]Lund, B., Kristjansen, P.E.G. and Hansen, H.H. (1993) "Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine)", Cancer Treatment Reviews 19, 45-55.
  • [Line 8048]Kaye, S.B (1994) "Gemcitabine: Current status phase I and II trials". Journal of Clinical Oncology 12, 1527-1531.
  • [Line 8076]Hertel, L.W., Boder, G.B., Kroin, J.S., Rinzel, S.M., Poore, G.A., Todd, G.C. and Grindley, G.B. (1990) "Evaluation of the antitumor activity of gemcitabine (2'.2'-difluoro-2'-deoxycytidine)". Cancer Research 50, 4417 4422.
  • [Line 8110]Braakhuis, B.J., Van Dongen, G.A., Vermorken, J.B. and Snow, G.B. (1991) "Preclinical in vivo activity of 2'.2"'-difluorodeoxy-cytidine (gemcitabine) against human head and neck cancer". Cancer Research 51, 211-214.
  • Ruiz van Haperen, V.W.T., Veerman, G., Vermorken, J.B. and Peters, G.J. (1994) "Improved antitumor effect of 2'.2'-difluorodeoxycytidine (gemcitabine) in murine colon carcinomas when administered as continuous infusion". Proceedings of the American Association for Cancer Research 35, 447.
  • [Line 8170]Abbruzzese, J.L., Grunewald, R., Wecks, E.A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., Raher, M.N. and Plunkett, W. (1991) "A phase I clinical, plasma, and cellular pharmacology study of gemcitabine". Journal of Clinical Oncology 9, 491-498.
  • [Line 8208]Grunewald, R., Kantarjian, H., Du, M., Faucher, K., Tarassoff, P. and Plunkett, W. (1992) "Gemcitabine in Leukemia: A phase I clinical, plasma, and cellular pharmacology study", Journal of Clinical Oncology 10, 406-413.
  • [Line 8241]Fosella, F., Abbruzzese, J., Pang, A., Gravel, D., Tarassoff, P., Lippman, S., Raber, M. and Hong, W.K. (1993) "Phase I studies of gemcitabine", European Journal of cancer 29 (Suppl. 6). s119.
  • Shephard, F., Cormier, Y., Burkes, R., Crump, M., Feld, R. and Strack, T. (1995) "Modified continual reassessment methodology: A superior way to assess toxicity in a phase I study of gemcitabine and cisplatin for non-small cell lung cancer". Proceedings of the American Society of Clinical Oncology 14, 358.
  • Allerheiligen, S., Johnson, R., Hatcher, B., Freeman, K., Tarnssoff, P., Voi, M. and Door, A. (1994) "Gemcitabine pharmacokinetics are influenced by gender, body surface area and duration of infusion", Proceedings of the American Society of Clinical Oncology 13, 136.
  • [Line 8338]Freeman, K.B., Anliker, S., Hamilton, M. Osbourne, D., Dhahir, P.H., Nelson, R. and Allerheiligen, S.R. (1995) "Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection". Journal of Chromatograph? Biomedical Applications 665, 171-181.
  • [Line 8372]Avramis, V.l., Biener, R., Krailo, M., Finkelstein, J., Ettinger, L., Willoughby, M., Siegel, S.E. and Holcenberg, J.S (1987) "Biochemical pharmacology of high-dose I-bela-D-arabinofurano-sylcytosine in childhood acute leukemia". Cancer Research 47, 6786-6792.
  • [Line 8407]Gandhi, V, Huang, P., Xn, Y.Z., Heinemann, V. and Plunkett, W. (1991) "Metabolism and action of 2'.2'-difluorndeotycytidine: SeIf-potentiation of cytotoxicity". Advances in Experimental Medicine and Biology 309A. 125-130.
  • [Line 8439]Grunewald, R., Abbruzzese, J.L., Tarassoff, P. and Plunkett, W. (1991) "Saturation of 2'.2'-difluorodeoxycytidine 5' triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine". Cancer Chemotherapy and Pharmacology 27, 258-262.
  • [Line 8470]Grunewald, R., Kantarjian, H., Keating, M.J., Abbnizzese, J., Tarassoff, P. and Plunket, W. (1990) "Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorndeoxycytidine (Gemcitabine) administration in leukemia". Cancer Research 50, 6823-6826.
  • [Line 8503]Pavlakis, N., Bell, O.K., Millward, M.J. and Levi, J.A. (1997) "Fatal pulmonary toxicity resulting from treatment with gemcitabine". Cancer 80, 286-291.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.